Invitris developed the worldwide first platform technology to synthesize arbitrary phages within a single system, thus enabling full scalability of therapeutic phage isolation, modification, production, and application.
Pedanius Therapeutics is developing RNAi therapeutics using two complimentary, bacterial delivery platform technologies silencing genes critical to bacterial growth and survival, thus introducing a versatile, novel modality into the battle against antimicrobial resistance
AMResolute is an early stage drug discovery and development company combating antibiotic-resistant bacterial infections through innovation, applying customised narrow spectrum antibiotics with a novel mode of action
Olgram is a preclinical stage biotechnology company, creating new drugs to fight bacterial persisters (bacteria in a dormant state responsible for infectious relapses), by using an original approach on new chemical entities discovered in the sea
Fagoterapia LAB is the biotech producing and commercializing tailor-made drugs based on good viruses (phage) to cure antibiotic resistant infections. To develop its products FL will leverage on a technology platform based on a proprietary AI-algorithm and on a phage biobank
At CC Bio, we harness the power of synthetic biology to engineer and edit the microbiome with precision antimicrobials. Our goal is to eliminate microbiome-based disease in a potent, specific and prophylactic fashion, harmonising the relationship between eukaryotic and microbial cells
With a new mechanism of action, a new class of compound and a new target, Disperazol is a robust, narrow-spectrum drug candidate with significant efficacy in inhibiting and dismantling Pseudomonas aeruginosa biofilms
The University Hospital Bonn together with Helmholtz Centre for Infection research develops the natural compound Corallopyronin A for difficult-to-treat Gram-positive infections, with funding from DZIF
Utilizing UV light, Puray provides the world’s first permanently disinfected medical tubing, offering superior infection prevention for patients
The following ventures were selected
at INCATE pitch events
LimmaTech Biologics AG is a clinical stage biopharmaceutical company focused on the development and manufacture of next generation vaccines for the prevention of life-threatening diseases.